ARCC 4 is a PROTAC, acting as an androgen receptor degrader. ARCC-4 is a low-nanomolar androgen receptor degrader able to degrade about 95% of cellular androgen receptors. ARCC-4 inhibits prostate tumor cell proliferation, degrades clinically relevant androgen receptor point mutants and unlike enzalutamide, retains antiproliferative effect in a high androgen environment. Thus, ARCC-4 exemplifies how protein degradation can address the drug resistance hurdles of enzalutamide.
CAS Number: 1973403-00-7
Molecular Weight: 1024.18
Related CAS Number:
1973403-00-7 (free base)
Chemical Name: (2S,4R)-1-[(2S)-2-(2-[4-[4-(4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]phenyl)phenoxy]butoxy]acetamido)-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide
Appearance: Solid Power.
Purity: ≥98% (or refer to the Certificate of Analysis)
Solubility: Soluble in DMSO
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥360 days if stored properly.
Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.
Drug Formulation: To be determined.
HS Tariff Code: 382200
How to use
ARCC-4 induces apoptosis and inhibiting proliferation of AR-amplified prostate cancer cells. ARCC-4 enhances protein-protein interactions between AR and VHL, thereby promoting the association of the trimeric complex. ARCC-4 (0.1-10, 000 nM; 20 hours) potently degrades AR with a D50 of 5 nM and Dmax of over 95%. ARCC-4 (100 nM; 12 hours) shows near complete AR degradation (>98%) in prostate cancer cells. ARCC-4 selectively degrades AR via the proteasome but not PR-A or PR-B suppression. ARCC-4 shows efficacy against clinically relevant AR mutations. ARCC-4 maintains activity despite elevated androgen levels.
- Salami J, Alabi S, Willard RR, Vitale NJ, Wang J, Dong H, Jin M, McDonnell DP, Crew AP, Neklesa TK, Crews CM. Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance. Commun Biol. 2018 Aug 2;1:100. doi: 10.1038/s42003-018-0105-8. eCollection 2018. PubMed PMID: 30271980; PubMed Central PMCID: PMC6123676.
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.